In RA patients, IL-17 neutralization yielded inconsistent results, with some studies reporting significant clinical response and improvements in patient-reported outcomes [77,78,79], whereas others failed to meet the primary efficacy end points [80,81,82]. This evidence concerns the gene IL17A and rheumatoid arthritis.